Effective inhibition of dengue virus replication using 3′UTR-targeted Vivo-Morpholinos
This study screened an effective vivo-MO target drug for the treatment of dengue virus infection, demonstrating low toxicity in mammalian cell lines, and proposed a novel preventive antiviral approach.
Authors
- Lifang Yu (ORCID: https://orcid.org/0000-0002-7066-9207)
- Mengwei Niu (ORCID: https://orcid.org/0009-0009-0860-4566)
- Ziyang Sheng (ORCID: https://orcid.org/0000-0001-7370-9465)
- Zhen Dong (ORCID: https://orcid.org/0000-0003-3108-0245)
- Oujia Zhang (ORCID: https://orcid.org/0009-0007-3146-531X)
- Hao Li (ORCID: https://orcid.org/0000-0002-8591-4105)
- Jing An (ORCID: https://orcid.org/0000-0002-2567-0380)
- Yansong Sun
- Xiao-Feng Li (ORCID: https://orcid.org/0000-0002-5014-7102)
- Xue Dong (ORCID: https://orcid.org/0000-0002-1417-6758)
- Wenyanbo Yi
- Yao Han
Institutions
- Capital Medical University (CN)
- Academy of Military Medical Sciences (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3389/fimmu.2024.1491230
- Citations
- 1
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- National Science Fund for Distinguished Young Scholars